Imugene Limited Secures $11 Million R&D Tax Refund
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy ?
Source: Business Insider
Imugene Limited Update: Imugene Limited has confirmed an $11 million R&D tax refund from the Australian Taxation Office, expected in January 2025, which will support its immuno-oncology pipeline aimed at improving cancer treatment.
Impact on Cancer Treatment: The company's innovative therapies are anticipated to significantly influence the global cancer treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
